

Garry G Graham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5077617/publications.pdf>

Version: 2024-02-01

61
papers

3,488
citations

218381

26
h-index

174990

52
g-index

63
all docs

63
docs citations

63
times ranked

4618
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Pharmacokinetics of Metformin. <i>Clinical Pharmacokinetics</i> , 2011, 50, 81-98.	1.6	910
2	Mechanism of Action of Paracetamol. <i>American Journal of Therapeutics</i> , 2005, 12, 46-55.	0.5	471
3	The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. <i>Inflammopharmacology</i> , 2013, 21, 201-232.	1.9	440
4	Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2157-2164.	0.5	160
5	Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol. <i>Clinical Pharmacokinetics</i> , 2007, 46, 623-644.	1.6	153
6	Tolerability of Paracetamol. <i>Drug Safety</i> , 2005, 28, 227-240.	1.4	120
7	Population Pharmacokinetics of Metformin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus: Simulation of Doses According to Renal Function. <i>Clinical Pharmacokinetics</i> , 2013, 52, 373-384.	1.6	98
8	Mechanisms of action of paracetamol and related analgesics. <i>Inflammopharmacology</i> , 2003, 11, 401-413.	1.9	74
9	The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis. <i>Drug Safety</i> , 2013, 36, 733-746.	1.4	69
10	Pharmacokinetics of Nonsteroidal Anti-Inflammatory Drugs in Synovial Fluid. <i>Clinical Pharmacokinetics</i> , 1999, 36, 191-210.	1.6	67
11	Stereoselective disposition of ibuprofen enantiomers in synovial fluid. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 43, 480-487.	2.3	62
12	Variability in Response to NSAIDs. <i>Drugs</i> , 1988, 36, 643-651.	4.9	60
13	Acetaminophen (paracetamol) inhibits myeloperoxidase-catalyzed oxidant production and biological damage at therapeutically achievable concentrations. <i>Biochemical Pharmacology</i> , 2010, 79, 1156-1164.	2.0	59
14	Stereoselective disposition of ibuprofen and flurbiprofen in rats. <i>Chirality</i> , 1990, 2, 134-140.	1.3	52
15	Pharmacokinetics of Ciprofloxacin in the Human Eye: a Clinical Study and Population Pharmacokinetic Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1674-1679.	1.4	52
16	¹ H, ¹³ C NMR, and electronic absorption spectroscopic studies of the interaction of cyanide with aurothiomalate. <i>Journal of Inorganic Biochemistry</i> , 1985, 25, 163-173.	1.5	47
17	Comparative Analgesia, Cardiovascular and Renal Effects of Celecoxib, Rofecoxib and Acetaminophen (Paracetamol). <i>Current Pharmaceutical Design</i> , 2002, 8, 1063-1075.	0.9	43
18	Salicylate metabolite kinetics after several salicylates. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 30, 266-275.	2.3	38

#	ARTICLE	IF	CITATIONS
19	The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes ^{II} . <i>Biochemical Pharmacology</i> , 1990, 39, 1697-1702.	2.0	35
20	Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat. <i>Clinical Pharmacokinetics</i> , 2017, 56, 459-475.	1.6	34
21	The Activation of Gold Complexes by Cyanide Produced by Polymorphonuclear Leukocytes. <i>Biochemical Pharmacology</i> , 1998, 56, 307-312.	2.0	33
22	Understanding the dose ^{II} response relationship of allopurinol: predicting the optimal dosage. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 932-938.	1.1	33
23	Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients. <i>Arthritis Research and Therapy</i> , 2012, 14, R189.	1.6	32
24	A Risk-Benefit Assessment of Paracetamol (Acetaminophen) Combined with Caffeine. <i>Pain Medicine</i> , 2010, 11, 951-965.	0.9	30
25	Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1363-1366.	0.5	30
26	A Bifunctional Role for Group IIA Secreted Phospholipase A2 in Human Rheumatoid Fibroblast-like Synoviocyte Arachidonic Acid Metabolism. <i>Journal of Biological Chemistry</i> , 2011, 286, 2492-2503.	1.6	29
27	The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes ^I . <i>Biochemical Pharmacology</i> , 1990, 39, 1687-1695.	2.0	28
28	Effects of tricyclic antidepressants on drug metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 1975, 18, 191-199.	2.3	24
29	The Cellular Metabolism and Effects of Gold Complexes. <i>Metal-Based Drugs</i> , 1994, 1, 395-404.	3.8	23
30	FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?. <i>Inflammopharmacology</i> , 2010, 18, 47-55.	1.9	22
31	Pharmacokinetics and metabolism of non ^{II} steroidal anti ^{II} inflammatory drugs. <i>Medical Journal of Australia</i> , 1987, 147, 597-602.	0.8	20
32	Disposition of and clinical response to salicylates in patients with rheumatoid disease. <i>Clinical Pharmacology and Therapeutics</i> , 1984, 35, 585-593.	2.3	13
33	Inhibition of prostaglandin synthesis in intact cells by paracetamol (acetaminophen). <i>Inflammopharmacology</i> , 2001, 9, 131-142.	1.9	13
34	Measurement of total phospholipids in urine of patients treated with gentamicin. <i>British Journal of Clinical Pharmacology</i> , 1997, 43, 435-440.	1.1	12
35	Pharmacokinetics of Metformin in Patients Receiving Regular Hemodiafiltration. <i>American Journal of Kidney Diseases</i> , 2016, 68, 990-992.	2.1	12
36	The safety and pharmacokinetics of metformin in patients with chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 565-575.	1.9	12

#	ARTICLE	IF	CITATIONS
37	Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysis. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2772-2783.	1.1	11
38	CHLORBUTOL TOXICITY AND DEPENDENCE. <i>Medical Journal of Australia</i> , 1979, 1, 288-288.	0.8	10
39	The pharmacokinetics of metformin and concentrations of haemoglobin A_{1C} and lactate in indigenous and non-indigenous Australians with type 2 diabetes mellitus. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 617-623.	1.1	8
40	Determination of febuxostat in human plasma by high performance liquid chromatography (HPLC) with fluorescence-detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1126-1127, 121764.	1.2	7
41	Tolerability of Paracetamol*. <i>Drugs</i> , 2003, 63, 39-42.	4.9	7
42	Non-steroidal Anti-inflammatory Drugs. , 2013, , 1-9.		6
43	Pharmacokinetic analysis of the time course of effect of atracurium. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 57, 390-397.	2.3	5
44	A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2486-2496.	1.1	4
45	Paracetamol should be first-line therapy in osteoarthritis. <i>Medical Journal of Australia</i> , 2005, 182, 198-199.	0.8	3
46	Comment on "Massive metformin overdose" by Chiew <i>et al</i> .. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2938-2939.	1.1	3
47	Limitations of drug concentrations used in cell culture studies for understanding clinical responses of NSAIDs. <i>Inflammopharmacology</i> , 2021, 29, 1261-1278.	1.9	3
48	STRESS IN MICE INCREASES INTRINSIC PENTOBARBITONE SENSITIVITY BY A PREDOMINANTLY PHARMACODYNAMIC MECHANISM. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1991, 18, 703-710.	0.9	2
49	Serum concentrations of estriol vary widely after application of vaginal oestriol cream. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2354-2360.	1.1	2
50	MULTIPLE DRUG INTERACTIONS WITH PHENYTOIN. <i>Medical Journal of Australia</i> , 1977, 2, 467-468.	0.8	2
51	Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 5359-5368.	1.1	2
52	Could metformin be used in patients with advanced chronic kidney disease?. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 302-303.	2.2	1
53	The Kinetics of Effect of Neuromuscular Blocking Drugs.. <i>Keio Journal of Medicine</i> , 1994, 43, 27-30.	0.5	1
54	Non-steroidal Anti-inflammatory Drugs: Overview. , 2016, , 986-993.		1

#	ARTICLE	IF	CITATIONS
55	Reactions of the Antiarthritic Drug Aurothiomalate With Phenylmercury(II) Compounds: NMR Studies. Metal-Based Drugs, 1996, 3, 269-276.	3.8	0
56	Restarting antidepressant and antipsychotic medication after intentional overdoses: need for evidence-based guidance. Therapeutic Advances in Psychopharmacology, 2019, 9, 204512531983688.	1.2	0
57	Salicylates. , 2013, , 1-6.		0
58	Antimalarial Drugs. , 2013, , 1-6.		0
59	Antimalarial Drugs. , 2016, , 97-101.		0
60	Salicylates. , 2016, , 1169-1174.		0
61	A Multicentre Open-Label Pharmacokinetic-Pharmacodynamic Study of Febuxostat in Patients with Chronic Gout. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-11-12.	0.0	0